Original text
Rate this translation
Your feedback will be used to help improve Google Translate
Home
Context Therapeutics Inc
Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers
Business
Dec 6 2022
3 min read

Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers

--News Direct--

Contact Details

Proactive Investors USA

Proactive Investors USA

+1 347-449-0879

na-editorial@proactiveinvestors.com

View original content to download multimedia: https://newsdirect.com/news/context-therapeutics-announces-bispecific-antibody-clinical-candidate-to-treat-cldn6-cancers-478676962